Loading clinical trials...
Loading clinical trials...
A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder (GAD) or Social Anxiety Disorder (SAD), Who Are Only Partial Responders to Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRI's) or Selective Serotonin Reuptake Inhibitors (SSRI's).
Conditions
Interventions
Namenda/Memantine
Locations
1
United States
SUNY Upstate Medical University Psychiatry Dept.
Syracuse, New York, United States
Start Date
December 1, 2006
Primary Completion Date
May 1, 2010
Completion Date
May 1, 2010
Last Updated
December 10, 2014
Lead Sponsor
State University of New York - Upstate Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions